3DIcon and Berkeley Lab Sign Agreement for Specialized Nanocrystals

3DIcon Corporation (OTCBB:TDCP), a developer of volumetric, three-dimension projection and display technologies, today announced that it has signed a Materials Transfer Agreement ("MTA") with the regents of the University of California through the Lawrence Berkeley National Laboratory ("Berkeley Lab") under which Berkeley Lab will provide specialized nanocrystals to 3DIcon.

"We have completed and patented the rendering of 3D applications. Our focus now is to improve the resolution, color, and scalability of the images," said Martin Keating, 3DIcon's founder and CEO.

CSpace® is designed to provide true, full-color, high-resolution, volumetric 360-degree, three-dimensional images without any viewing aids such as special glasses. It is the first proven technology of its kind that has no mechanical moving parts. 3D display systems developed using CSpace will have the potential to enhance significantly such applications as medical imaging, surgical planning, full-body scans, aircraft manufacturing and maintenance, military command and control, baggage and cargo scanning, and entertainment. 3DIcon's current efforts include discussions with potential partners in furtherance of its goal of aggressively pursuing the commercialization of CSpace in a variety of applications.

Source: http://www.3dicon.net/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.